DEEMD: Drug Efficacy Estimation against SARS-CoV-2 based on cell Morphology with Deep multiple instance learning

• URL: http://arxiv.org/abs/2105.05758v1
• Date: Mon, 10 May 2021 20:38:34 GMT
• Title: DEEMD: Drug Efficacy Estimation against SARS-CoV-2 based on cell Morphology with Deep multiple instance learning
• Authors: M.Sadegh Saberian, Kathleen P. Moriarty, Andrea D. Olmstead, Ivan R. Nabi, Fran\c{c}ois Jean, Maxwell W. Libbrecht, Ghassan Hamarneh
• Abstract summary: Drug repurposing can accelerate the identification of effective compounds for clinical use against SARS-CoV-2. DEEMD is a computational pipeline using deep neural network models within a multiple instance learning framework. DEEMD identifies known SARS-CoV-2 inhibitors, such as Remdesivir and Aloxistatin, supporting the validity of our approach.
• Score: 8.716655008588361
• License: http://creativecommons.org/licenses/by-sa/4.0/
• Abstract: Drug repurposing can accelerate the identification of effective compounds for clinical use against SARS-CoV-2, with the advantage of pre-existing clinical safety data and an established supply chain. RNA viruses such as SARS-CoV-2 manipulate cellular pathways and induce reorganization of subcellular structures to support their life cycle. These morphological changes can be quantified using bioimaging techniques. In this work, we developed DEEMD: a computational pipeline using deep neural network models within a multiple instance learning (MIL) framework, to identify putative treatments effective against SARS-CoV-2 based on morphological analysis of the publicly available RxRx19a dataset. This dataset consists of fluorescence microscopy images of SARS-CoV-2 non-infected cells and infected cells, with and without drug treatment. DEEMD first extracts discriminative morphological features to generate cell morphological profiles from the non-infected and infected cells. These morphological profiles are then used in a statistical model to estimate the applied treatment efficacy on infected cells based on similarities to non-infected cells. DEEMD is capable of localizing infected cells via weak supervision without any expensive pixel-level annotations. DEEMD identifies known SARS-CoV-2 inhibitors, such as Remdesivir and Aloxistatin, supporting the validity of our approach. DEEMD is scalable to process and screen thousands of treatments in parallel and can be explored for other emerging viruses and datasets to rapidly identify candidate antiviral treatments in the future.

Related papers

• Estimating the Causal Effects of T Cell Receptors [20.01390828400336]
  We introduce a method to infer the causal effects of T cell receptor sequences on patient outcomes. Our approach corrects for unobserved confounders, such as a patient's environment and life history. As a demonstration, we use it to analyze the effects of TCRs on COVID-19 severity.
  arXiv  Detail & Related papers  (2024-10-18T02:45:14Z)
• Benchmarking Machine Learning Robustness in Covid-19 Genome Sequence Classification [109.81283748940696]
  We introduce several ways to perturb SARS-CoV-2 genome sequences to mimic the error profiles of common sequencing platforms such as Illumina and PacBio. We show that some simulation-based approaches are more robust (and accurate) than others for specific embedding methods to certain adversarial attacks to the input sequences.
  arXiv  Detail & Related papers  (2022-07-18T19:16:56Z)
• COVID-Net Biochem: An Explainability-driven Framework to Building Machine Learning Models for Predicting Survival and Kidney Injury of COVID-19 Patients from Clinical and Biochemistry Data [66.43957431843324]
  We introduce COVID-Net Biochem, a versatile and explainable framework for constructing machine learning models. We apply this framework to predict COVID-19 patient survival and the likelihood of developing Acute Kidney Injury during hospitalization.
  arXiv  Detail & Related papers  (2022-04-24T07:38:37Z)
• Using Deep Learning Sequence Models to Identify SARS-CoV-2 Divergence [1.9573380763700707]
  SARS-CoV-2 is an upper respiratory system RNA virus that has caused over 3 million deaths and infecting over 150 million worldwide as of May 2021. We propose a neural network model that leverages recurrent and convolutional units to take in amino acid sequences of spike proteins and classify corresponding clades.
  arXiv  Detail & Related papers  (2021-11-12T07:52:11Z)
• Lung Cancer Lesion Detection in Histopathology Images Using Graph-Based Sparse PCA Network [93.22587316229954]
  We propose a graph-based sparse principal component analysis (GS-PCA) network, for automated detection of cancerous lesions on histological lung slides stained by hematoxylin and eosin (H&E) We evaluate the performance of the proposed algorithm on H&E slides obtained from an SVM K-rasG12D lung cancer mouse model using precision/recall rates, F-score, Tanimoto coefficient, and area under the curve (AUC) of the receiver operator characteristic (ROC)
  arXiv  Detail & Related papers  (2021-10-27T19:28:36Z)
• A k-mer Based Approach for SARS-CoV-2 Variant Identification [55.78588835407174]
  We show that preserving the order of the amino acids helps the underlying classifiers to achieve better performance. We also show the importance of the different amino acids which play a key role in identifying variants and how they coincide with those reported by the USA's Centers for Disease Control and Prevention (CDC)
  arXiv  Detail & Related papers  (2021-08-07T15:08:15Z)
• CovidDeep: SARS-CoV-2/COVID-19 Test Based on Wearable Medical Sensors and Efficient Neural Networks [51.589769497681175]
  The novel coronavirus (SARS-CoV-2) has led to a pandemic. The current testing regime based on Reverse Transcription-Polymerase Chain Reaction for SARS-CoV-2 has been unable to keep up with testing demands. We propose a framework called CovidDeep that combines efficient DNNs with commercially available WMSs for pervasive testing of the virus.
  arXiv  Detail & Related papers  (2020-07-20T21:47:28Z)
• Machine-Learning Driven Drug Repurposing for COVID-19 [0.47791962198275073]
  We aim to discover the underlying associations between viral proteins and antiviral therapeutics by employing neural network models. We trained ANN models with virus protein sequences as inputs and antiviral agents deemed safe-in-humans as outputs. Using sequences for SARS-CoV-2 as inputs to the trained models produces tentative safe-in-human antiviral candidates for treating COVID-19.
  arXiv  Detail & Related papers  (2020-06-25T21:18:53Z)
• Gaining Insight into SARS-CoV-2 Infection and COVID-19 Severity Using Self-supervised Edge Features and Graph Neural Networks [8.980876474818153]
  We seek to use deep learning to study the biology of SARS-CoV-2 infection and COVID-19 severity. We propose a model that builds on Graph Attention Networks (GAT), creates edge features using self-supervised learning, and ingests these edge features via a Set Transformer. We apply our model to single-cell RNA sequencing datasets of SARS-CoV-2 infected lung organoids and bronchoalveolar lavage fluid samples of patients with COVID-19.
  arXiv  Detail & Related papers  (2020-06-23T13:22:16Z)
• Continuous Learning and Inference of Individual Probability of SARS-CoV-2 Infection Based on Interaction Data [0.0]
  This study presents a new approach to determine the likelihood of asymptomatic carriers of the SARS-CoV-2 virus by using interaction-based continuous learning and inference of individual probability (CLIIP) for contagious ranking. Compared to traditional contact tracing methods, our approach significantly reduces the screening and quarantine required to search for the potential asymptomatic virus carriers by as much as 94%.
  arXiv  Detail & Related papers  (2020-06-08T14:52:04Z)
• COVID-Net S: Towards computer-aided severity assessment via training and validation of deep neural networks for geographic extent and opacity extent scoring of chest X-rays for SARS-CoV-2 lung disease severity [58.23203766439791]
  Chest x-rays (CXRs) are often used to assess SARS-CoV-2 severity. In this study, we assess the feasibility of computer-aided scoring of CXRs of SARS-CoV-2 lung disease severity using a deep learning system.
  arXiv  Detail & Related papers  (2020-05-26T16:33:52Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.